Operational review
An important milestone was achieved in February, when we received ethics approval to commence the human trial for the treatment of a sub-type of irritable bowel syndrome (IBS) using our Gastrointestinal ReProgramming (GaRP) complementary medicine. This randomised, double-blind, placebo-controlled trial will be conducted in two stages as a virtual trial, with minimal on-site visits and participants completing assessments online. The trial will use up to six sites and approximately 200 participants will enrol. Due to a scheduling delay in availability of the placebo from reduced manufacturing shifts under COVID-19 restrictions, recruitment for the trial is now commencing in
In April, we also received approval from the
3FDC is targeted to release from the junction between the small and large intestine (ileocecal junction) and exert its effects on the microbiome in the large intestine. The coated delivery of these 3FDC components to the large intestine is considered important for gut-brain axis balance, in part due to influences on microbiome homeostasis and metabolites. The
The
During the year we substantially progressed our animal health studies, where we are targeting the need for growth enhancement feed products, without antibiotics or zinc oxide.
Our activities prioritised removing barriers to out-licensing Detach(R) through the progression of challenge trials for our piglet and poultry formulations.
In February, we announced the successful completion of the poultry challenge trial testing "Efficacy of ANRpf on the performance of broilers subject to subclinical and necrotic enteritis challenges". ANF-pf is our proprietary enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method. The study was a randomised, placebo controlled trial. The parameters analysed were bird weight gain, feed intake, feed conversion ratio and other complex parameters. The initial results were extremely encouraging, with statistical significance demonstrated across multiple parameters.
Further work to optimise the dose and dosing regimen are required to fully understand the commercial opportunity and the product's value.
The BONIFF-SMEC piglet challenge study for Escherichia Coli commenced in April and was completed in June, at
Pleasingly, we could conclude that under the conditions of the proof-of-concept study, BONIFF could be considered as a replacement for zinc oxide with commercial levels of additives, in a semi-moist extruded creep (SMEC) piglet diet . While the commercial opportunity here is still being established ,the initial indications are that BONIFF can be added to feed at a significant saving per tonne compared to the current regime of non-physiological levels zinc oxide combined with commercial levels of additives such as organic acids.
Medicinal use of zinc oxide will be banned in
Patent for Detach(R)
In April, we were granted a patent for our Detach(R) animal health product, which strengthened our intellectual property position in the treatment of, and prevention of, diarrhoea caused by pathogenic microbes. The patent provides the pathway for us to further pursue commercialisation opportunities and expires on
Partnering discussions
During the year we progressed licensing discussions for GaRP with international consumer health companies. We are highly encouraged by our discussions to date with potential partners, and following the completion of our IBS human trial in
Financial position
Despite the delays to the commencement of our human trials, we remain in a robust financial position, ending FY21 with cash at bank of
During the year to
To view the full Annual Report, please visit:
https://abnnewswire.net/lnk/A2N0JA1Y
About
Contact:
Steven Lydeamore
CEO,
+61 (0) 438 027 172
slydeamore@anatara.com
Market Eye
+61 (0) 417 311 335
eric.kuret@marketeye.com.au
Copyright (C) 2021 ABN Newswire. All rights reserved., source